

Nazia Chaudhuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8772681/publications.pdf>

Version: 2024-02-01

96
papers

2,477
citations

279487

23
h-index

214527

47
g-index

100
all docs

100
docs citations

100
times ranked

3233
citing authors

#	ARTICLE	IF	CITATIONS
1	Nintedanib in patients with progressive fibrosing interstitial lung diseasesâ€™ subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 453-460.	5.2	331
2	Drug-Induced Interstitial Lung Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2018, 7, 356.	1.0	215
3	Idiopathic Pulmonary Fibrosis (IPF): An Overview. <i>Journal of Clinical Medicine</i> , 2018, 7, 201.	1.0	215
4	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1656-1665.	2.5	171
5	The therapy of idiopathic pulmonary fibrosis: what is next?. <i>European Respiratory Review</i> , 2019, 28, 190021.	3.0	157
6	Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. <i>Journal of Clinical Medicine</i> , 2016, 5, 78.	1.0	139
7	Association of Cardiovascular Disease With Respiratory Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2166-2177.	1.2	104
8	Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases. <i>International Journal of Audiology</i> , 2020, 59, 889-890.	0.9	73
9	Toll-like receptors and chronic lung disease. <i>Clinical Science</i> , 2005, 109, 125-133.	1.8	66
10	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 771-779.	5.2	65
11	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. <i>European Respiratory Journal</i> , 2020, 55, 1901760.	3.1	61
12	Summary of the British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults. <i>Thorax</i> , 2013, 68, 786-787.	2.7	60
13	Real world experiences: Pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2014, 108, 224-226.	1.3	60
14	Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880061.	1.0	59
15	Treatment of fibrotic interstitial lung disease: current approaches and future directions. <i>Lancet</i> , 2021, 398, 1450-1460.	6.3	47
16	Reducing the Toll of Inflammatory Lung Disease. <i>Chest</i> , 2007, 131, 1550-1556.	0.4	46
17	IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe. <i>Advances in Therapy</i> , 2015, 32, 87-107.	1.3	44
18	A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre. <i>Journal of Clinical Medicine</i> , 2016, 5, 66.	1.0	44

#	ARTICLE	IF	CITATIONS
19	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. <i>Respiration</i> , 2019, 97, 173-184.	1.2	39
20	The burden of progressive fibrotic interstitial lung disease across the UK. <i>European Respiratory Journal</i> , 2021, 58, 2100221.	3.1	39
21	Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. <i>Clinical and Translational Medicine</i> , 2017, 6, 41.	1.7	32
22	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. <i>European Respiratory Journal</i> , 2021, 58, 2001518.	3.1	30
23	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). <i>BMJ Open Respiratory Research</i> , 2021, 8, e001049.	1.2	28
24	Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. <i>Respiratory Research</i> , 2019, 20, 7.	1.4	25
25	Diesel Exhaust Particle Exposure In Vitro Alters Monocyte Differentiation and Function. <i>PLoS ONE</i> , 2012, 7, e51107.	1.1	24
26	Basic science of the innate immune system and the lung. <i>Paediatric Respiratory Reviews</i> , 2008, 9, 236-242.	1.2	23
27	Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service. <i>Advances in Therapy</i> , 2021, 38, 4505-4519.	1.3	23
28	Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age. <i>Journal of Thoracic Disease</i> , 2017, 9, 4700-4707.	0.6	22
29	No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone. <i>European Respiratory Journal</i> , 2019, 53, 1801060.	3.1	22
30	Substrate for the Myocardial Inflammation-Heart Failure Hypothesis Identified Using Novel SPIO Methodology. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 365-376.	2.3	20
31	Bagpipe lung; a new type of interstitial lung disease?. <i>Thorax</i> , 2017, 72, 380-382.	2.7	17
32	Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019. <i>ERJ Open Research</i> , 2021, 7, 00187-2020.	1.1	17
33	Sarcoidosis in the UK: insights from British Thoracic Society registry data. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000357.	1.2	16
34	Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment. <i>Advances in Therapy</i> , 2021, 38, 268-277.	1.3	13
35	Conventional oxygen therapy versus CPAP as a ceiling of care in ward-based patients with COVID-19: a multi-centre cohort evaluation. <i>EClinicalMedicine</i> , 2021, 40, 101122.	3.2	13
36	Drug induced interstitial lung disease: a systematic review. , 2018, , .		12

#	ARTICLE	IF	CITATIONS
37	Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?. <i>Drugs and Aging</i> , 2017, 34, 647-653.	1.3	10
38	Myocardial involvement in eosinophilic granulomatosis with polyangiitis evaluated with cardiopulmonary magnetic resonance. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1371-1381.	0.7	10
39	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. <i>Frontiers in Medicine</i> , 2021, 8, 699644.	1.2	8
40	Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review. <i>Advances in Therapy</i> , 2019, 36, 2193-2204.	1.3	7
41	S91â€¦A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100 mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis. <i>Thorax</i> , 2015, 70, A52.1-A52.	2.7	6
42	The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 1001-1008.	1.0	6
43	Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib. <i>Clinical Medicine Insights Therapeutics</i> , 2017, 9, 1179559X1771912.	0.4	5
44	Physiological predictors of Hypoxic Challenge Testing (HCT) outcomes in Interstitial Lung Disease (ILD). <i>Respiratory Medicine</i> , 2018, 135, 51-56.	1.3	5
45	A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey. , 2018, , .		5
46	Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, 218-224.	0.2	5
47	How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians. <i>ERJ Open Research</i> , 2020, 6, 00286-2019.	1.1	4
48	P28â€¦Real World MDT Diagnosis of Idiopathic Pulmonary Fibrosis. <i>Thorax</i> , 2015, 70, A90.1-A90.	2.7	3
49	Feather bedding as a cause of hypersensitivity pneumonitis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, hcx010.	0.2	3
50	Pulmonary Therapy Podcastâ€”COVID-19: Research and Real-World Experiences from the Editorial Board. <i>Pulmonary Therapy</i> , 2021, 7, 1-7.	1.1	2
51	P168â€¦Patient symptoms following discharge from hospital after COVID-19 Pneumonia. , 2021, , .		2
52	Adherence to home spirometry among patients with IPF: results from the INMARK trial. , 2019, , .		2
53	Interstitial lung disease associated with ANCA positivity: a retrospective analysis. , 2019, , .		2
54	Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?. , 2020, , .		2

#	ARTICLE	IF	CITATIONS
55	Idiopathic pulmonary fibrosis: a clinical update. British Journal of General Practice, 2018, 68, 249-250.	0.7	1
56	Treatment of severe idiopathic pulmonary fibrosisâ€”is sildenafil the next (in)stage?. Journal of Thoracic Disease, 2019, 11, 339-340.	0.6	1
57	Beware Weakening the Ivory Tower of MDT Diagnosis in Interstitial Lung Disease. Journal of Clinical Medicine, 2019, 8, 1964.	1.0	1
58	Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?. , 2018, , .		1
59	Oxygen enhanced MRI biomarkers of lung function in interstitial lung disease. , 2020, , .		1
60	Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 231-233.	0.2	1
61	IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK. , 2015, , .		1
62	First insights from the BTS idiopathic pulmonary fibrosis (IPF) registry. , 2016, , .		1
63	Hyperpolarised 129-xenon diffusion-weighted MRI in interstitial lung disease. , 2019, , .		1
64	Longitudinal change in hyperpolarised 129-xenon MR spectroscopy in interstitial lung disease. , 2019, , .		1
65	Diesel Exhaust Particles Alter Monocyte Differentiation In Vitro. , 2010, , .		0
66	S13â€”Sole use of forced vital capacity as per national institute of health and care excellence criteria disadvantage 2 in 5 people with idiopathic pulmonary fibrosis. Thorax, 2013, 68, A10.1-A10.	2.7	0
67	P280 Extended Clinical Experience With Pirfenidone During A Named Patient Programme For Idiopathic Pulmonary Fibrosis (ipf): Interim Results. Thorax, 2014, 69, A196-A196.	2.7	0
68	M263 A Quarter Of IpF Patients Not Eligible For Pirfenidone Treatment Due To The Nice Criteria Significantly Decline Over Time. Thorax, 2014, 69, A218-A218.	2.7	0
69	M264 Health And Economic Impact Of Prescribing Pirfenidone. Thorax, 2014, 69, A218-A219.	2.7	0
70	P6â€”Early Clinical Experience With Nintedanib â€” a two centre review. Thorax, 2015, 70, A77.2-A77.	2.7	0
71	P34â€”Sarcoidosis and co-existent Aspergillus lung disease. Thorax, 2015, 70, A92.3-A93.	2.7	0
72	Nintedanib for treating idiopathic pulmonary fibrosis. British Journal of Health Care Management, 2016, 22, 250-251.	0.1	0

#	ARTICLE	IF	CITATIONS
73	P151â€¦The role of bronchoalveolar lavage and its quality in the diagnosis of interstitial lung disease. , 2017, , .		0
74	M24â€¦Do antifibrotics impact on lung transplantation outcomes in idiopathic pulmonary fibrosis?. , 2017, , .		0
75	P157â€¦Can baseline physiological tests help predict the outcome of hypoxic challenge testing (hct) in interstitial lung disease (ild)?. , 2017, , .		0
76	P148â€¦Idiopathic pulmonary fibrosis: â€œlost in the systemâ€ in the north west of england?. , 2017, , .		0
77	Prevalence of incidental interstitial lung disease in the Manchester lung cancer screening pilot. Lung Cancer, 2019, 127, S23-S24.	0.9	0
78	AB0593â€¦INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANCA POSITIVITY: A RETROSPECTIVE ANALYSIS. , 2019, , .		0
79	Comment from the Editor of the Special Issue: â€œLung Disease on COPD, Asthma, Bronchiectasis, Lung Cancer Screening, IPFâ€ Journal of Clinical Medicine, 2019, 8, 2060.	1.0	0
80	Reply to Althwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 522-524.	2.5	0
81	Sarcoidosis in the UK: Insights from the BTS interstitial lung disease registry. , 2016, , .		0
82	Clinical experience with nintedanib for IPF in 3 UK tertiary referral centres. , 2016, , .		0
83	The impact of a network based approach on lung function and symptom duration at diagnosis in idiopathic pulmonary fibrosis. , 2018, , .		0
84	What can we learn from Idiopathic Pulmonary Fibrosis Registries?. , 2018, , .		0
85	Antifibrotic choice in idiopathic pulmonary fibrosis. , 2018, , .		0
86	Breath Biomarkers in Idiopathic Pulmonary Fibrosis: A Systematic Review. , 2018, , .		0
87	Predictive variables to obtain a bronchoalveolar lavage of adequate quality in patients with interstitial lung diseases. , 2019, , .		0
88	Association of demographic, laboratory and clinical parameters with HRCT-chest findings in patients with sarcoidosis. , 2019, , .		0
89	Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre. , 2019, , .		0
90	P56â€¦What happens to patients with idiopathic pulmonary fibrosis who are not eligible for antifibrotic treatment due to current NICE guidelines. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	S125â€¦Quantitative CT and hyperpolarised 129-xenon diffusion-weighted MRI in interstitial lung disease. , 2019, , .		0
92	Pulmonary involvement in antiphospholipid syndrome. , 2019, , 124-139.		0
93	Exhaled volatile organic compounds in idiopathic pulmonary fibrosis and disease progression. , 2020, , .		0
94	Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON. , 2021, , .		0
95	The impact of Covid-19 on hospital length of stay and resources: an experience from a tertiary respiratory centre in the UK. , 2021, , .		0
96	Admission clinical parameters in predicting in-hospital mortality in COVID-19. , 2021, , .		0